Prakiraan pendapatan perusahaan: Silexion Therapeutics Corp. (SLXN)

Silexion Therapeutics (SLXN) - logo korporat

On GURU.Markets, the sales benchmark for Silexion Therapeutics Corp (SLXN) demonstrates the potential of RNA therapy, where 0.00 represents the latest metric reading. Silexion Therapeutics Corp (SLXN) is implementing targeted drug delivery into neoplasms to neutralize complex genetic malfunctions. The use of the SILENSEED system enables the suppression of the KRAS gene, paving the way for the treatment of aggressive pancreatic cancer.

Volume dodolan sing dikarepake perusahaan: Silexion Therapeutics Corp (SLXN) kanggo 17.08.2024 - 18.11.2026

Ringkesan rincian data analitis Silexion Therapeutics (SLXN)

Pambiji fundamental:Silexion Therapeutics SLXN
Sampel barang silexion.com

Investors assess the resilience of a business model by balancing current expenditures against future revenue. At Silexion Therapeutics Corp (SLXN), this depends directly on the ability to retain leading oncologists to execute the R&D strategy in RNA therapy. This indicator calculates the expected cash flow from future commercial products, reflecting the market value of potential sales. By analyzing the trend of the company's prospective sales, one can identify an undervalued asset. This allows for an objective correlation between market capitalization and the long-term development prospects of the business.

Pesaing wigati

Prakiraan pendapatan perusahaan Incyte Pharma (INCY)|Prakiraan pendapatan perusahaan HCM (Hutchison MediPharma)|Prakiraan pendapatan perusahaan Nuvation Pharma NUVB|Day One Biopharmaceuticals Inc - Prakiraan pendapatan perusahaan|MNPR - Prakiraan pendapatan perusahaan|Volume dodolan sing dikarepake perusahaan Inhibrx Biosciences|IMAB: Prakiraan volume dodolan|Prakiraan dodolan perusahaan Fennec Pharmaceuticals Inc FENC|Volume dodolan mangsa ngarep perusahaan HRTX|Volume dodolan sing dikarepake perusahaan Nuvectis Pharma, Inc. NVCT|Volume dodolan mangsa ngarep perusahaan CHRS (Coherus BioSciences, Inc)|CRBP (Corbus Pharmaceuticals Holdings) - Pendapatan mangsa ngarep perusahaan|Cardiff Oncology - Volume dodolan mangsa ngarep perusahaan|Prakiraan volume pendapatan perusahaan BYSI (BeyondSpring)|BioAtla - Prakiraan volume dodolan|Pendapatan mangsa ngarep perusahaan LIXT (Lixte Biotechnology Holdings)|CTXR: Prakiraan volume dodolan|Volume dodolan sing dikarepake perusahaan cellectar.com (CLRB)|Prakiraan pendapatan perusahaan BioLineRx|CANF: Pendapatan mangsa ngarep perusahaan|Prakiraan volume dodolan APRE|Prakiraan volume dodolan Kazia Therapeutics Ltd (KZIA)|Prakiraan pendapatan perusahaan NuCana PLC NCNA|CMRX (Chimerix) - Pendapatan sing dikarepake perusahaan|CYCC: Volume dodolan mangsa ngarep perusahaan|Volume dodolan sing dikarepake perusahaan g1therapeutics.com|Kronos Bio Inc (KRON) - Prakiraan pendapatan perusahaan|Kintara (KTRA) - Prakiraan volume dodolan|Prakiraan pendapatan perusahaan Oncternal Therapeutics, Inc.|Volume dodolan sing dikarepake perusahaan portagebiotech.com PRTG